nivolumab,ipilimumab
bms
['niche2']
 s #niche2 population with 31% of patients with an underlying #lynchsyndrome #esmo22 
#MedicalOncologist tweeting on #immunotherapy, #drugdevelopment, #COVID19 & #HealthEcon. #NCI #CancerMoonshot Adult Immunotherapy Co-Chair. Tweets are mine.